Zeb1 mediates injury-induced mesenchymal transition in the mouse corneal endothelium in vivo
Listen to this summary
The authors investigate the role of Zeb1 in mediating injury-induced mesenchymal transition in the corneal endothelium and its contribution to fibrosis. They demonstrate that targeting Zeb1 through conditional knockout in a mouse model significantly inhibits the expression of mesenchymal transition-related genes and reduces corneal edema and retrocorneal membrane formation following injury. These findings suggest that ZEB1 signaling could be a potential therapeutic target for treating corneal blindness without the need for transplantation.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.

More from American journal of ophthalmology
View all →Jun 24, 2026 · American journal of ophthalmology
Corneal Epithelial Alterations Associated With CDK4/6 Inhibitor Therapy in Hormone Receptor-Positive Breast Cancer
Jun 24, 2026 · American journal of ophthalmology
The Impact of PCSK9 Inhibitors on Development of Retinal Vascular Occlusions
Jun 23, 2026 · American journal of ophthalmology
Associations Between Routine Vaccinations and the Risk of New-Onset Idiopathic Uveitis
Jun 23, 2026 · American journal of ophthalmology
Dopamine-Enhancing Therapies and Risk of Neovascular AMD Conversion: A Target Trial Emulation
Jun 22, 2026 · American journal of ophthalmology
Association between statin use and dry eye disease: A systematic review and meta-analysis
Jun 22, 2026 · American journal of ophthalmology
Therapeutic response to anti-VEGF retreatment among eyes with stabilized vision after being lost to follow-up in diabetic macular edema: A nationwide, registry-based cohort study
More in Ophthalmology
View all →Jun 24, 2026 · Lancet (London, England)
Efficacy and safety of tirofiban after successful endovascular reperfusion in acute ischaemic stroke (ATTRACTION) in China: a multicentre, double-blind, randomised controlled trial
Jun 24, 2026 · The New England journal of medicine
A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant Tuberculosis
Jun 24, 2026 · The New England journal of medicine
Prevention and Treatment of Peanut Allergy
Jun 24, 2026 · Lancet (London, England)
Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study
Jun 24, 2026 · The New England journal of medicine
Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas
Jun 23, 2026 · Lancet (London, England)
Combined bladder-kidney transplantation: first-in-human feasibility trial
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR


